{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:26:01Z","timestamp":1773307561472,"version":"3.50.1"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bcp.2020.113895","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T02:13:00Z","timestamp":1583287980000},"page":"113895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?"],"prefix":"10.1016","volume":"177","author":[{"given":"Paolo","family":"Gelosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Castiglioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Camera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-3454","authenticated-orcid":false,"given":"Luigi","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.113895_b0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(15)60635-3","article-title":"Cancer and cardiovascular disease: more tightly linked than by chance","volume":"385","author":"Opie","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bcp.2020.113895_b0010","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2020.113895_b0015","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.bcp.2020.113895_b0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7326\/M18-0737","article-title":"Clonal hematopoiesis confers predisposition to both cardiovascular disease and cancer: a newly recognized link between two major killers","volume":"169","author":"Ebert","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0025","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.113895_b0040","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/CIRCULATIONAHA.118.033907","article-title":"Heart disease and cancer","volume":"138","author":"Kitsis","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.bcp.2020.113895_b0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm1447","article-title":"Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma","volume":"12","author":"Thaker","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy","volume":"23","author":"Tang","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2020.113895_b0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-009-1136-0","article-title":"Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma","volume":"66","author":"Otake","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113895_b0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11605-007-0403-9","article-title":"Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1\/2 signaling","volume":"12","author":"Anandanadesan","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.bcp.2020.113895_b0065","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ijc.27712","article-title":"Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model","volume":"132","author":"Chirasani","year":"2013","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.bcp.2020.113895_b0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phrs.2014.11.006","article-title":"Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation \u2013 Impact of Ras-\/Rho-prenylation","volume":"91","author":"Afshordel","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2020.113895_b0075","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-9966-30-74","article-title":"Statin-induced apoptosis via the suppression of ERK1\/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma","volume":"30","author":"Yanae","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.113895_b0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01612908","article-title":"Functional beta-adrenergic receptors in breast cancer cells","volume":"116","author":"Vandewalle","year":"1990","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/carcin\/22.3.473","article-title":"Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas","volume":"22","author":"Weddle","year":"2001","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.bcp.2020.113895_b0095","first-page":"2866","article-title":"Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers","volume":"61","author":"Masur","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.113895_b0100","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/1535-7163.MCT-12-0809","article-title":"Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling","volume":"12","author":"Guo","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.113895_b0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/cbt.10.1.11944","article-title":"\u03b22-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF\u03baB and AP-1","volume":"10","author":"Zhang","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2020.113895_b0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcp.25092","article-title":"Selective \u03b22-AR blockage suppresses colorectal cancer growth through regulation of EGFR-Akt\/ERK1\/2 signaling, G1-phase arrest, and apoptosis","volume":"231","author":"Chin","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2020.113895_b0115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","article-title":"Association between use of \u03b2-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease","volume":"65","author":"Grytli","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2020.113895_b0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24582","article-title":"Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation","volume":"92","author":"Hwa","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcp.2020.113895_b0125","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41598-017-02913-8","article-title":"Pre- and post-diagnostic \u03b2-blocker use and lung cancer survival: a population-based cohort study","author":"Weberpals","year":"2017","journal-title":"Sci. Rep. 7"},{"key":"10.1016\/j.bcp.2020.113895_b0130","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ijc.30717","article-title":"Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: results from a population-based study","volume":"141","author":"Jansen","year":"2017","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.bcp.2020.113895_b0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-13-85","article-title":"Use of \u00df-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study","volume":"13","author":"Johannesdottir","year":"2013","journal-title":"BMC Cancer."},{"key":"10.1016\/j.bcp.2020.113895_b0140","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients","volume":"11","author":"Na","year":"2018","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.bcp.2020.113895_b0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.bcp.2020.113895_b0150","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","article-title":"Meta-analysis of the effects of beta blocker on survival time in cancer patients","volume":"140","author":"Choi","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","article-title":"\u03b2-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"25","author":"Zhong","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.bcp.2020.113895_b0160","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10654-017-0304-5","article-title":"Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis","volume":"32","author":"Weberpals","year":"2017","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.bcp.2020.113895_b0165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.leu.2402476","article-title":"HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis","volume":"16","author":"Wong","year":"2002","journal-title":"Leukemia."},{"key":"10.1016\/j.bcp.2020.113895_b0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","article-title":"Statin drugs to reduce breast cancer recurrence and mortality","volume":"20","author":"Beckwitt","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2020.113895_b0175","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.drudis.2019.03.010","article-title":"Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing","volume":"24","author":"Regulska","year":"2019","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.bcp.2020.113895_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197422","article-title":"Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling","volume":"13","author":"Beckwitt","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.bcp.2020.113895_b0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pupt.2013.06.005","article-title":"Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents","volume":"27","author":"Capra","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113895_b0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1098-8823(03)00045-5","article-title":"Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells","volume":"71","author":"Capra","year":"2003","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.bcp.2020.113895_b0195","doi-asserted-by":"crossref","first-page":"re1-re1","DOI":"10.1126\/stke.2000.40.re1","article-title":"Regulation of Mitogen-Activated Protein Kinase Signaling Networks by G Protein-Coupled Receptors","volume":"2000","author":"Gutkind","year":"2000","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bcp.2020.113895_b0200","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3892\/or.2015.3741","article-title":"Statins are potential anticancerous agents (Review)","volume":"33","author":"Altwairgi","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.113895_b0205","article-title":"Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113895_b0210","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.371","article-title":"A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI\/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer","volume":"113","author":"Lim","year":"2015","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.bcp.2020.113895_b0215","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10637-014-0075-8","article-title":"A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer","volume":"32","author":"Lee","year":"2014","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.bcp.2020.113895_b0220","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4143\/crt.2016.546","article-title":"Randomized phase II study of afatinib plus simvastatin versus afatinib alone in previously treated patients with advanced nonadenocarcinomatous non-small cell lung cancer","volume":"49","author":"Lee","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2020.113895_b0225","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bjh.13035","article-title":"SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia","volume":"167","author":"Advani","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2020.113895_b0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2018.01.021","article-title":"Report of the relapsed\/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)","volume":"67","author":"Advani","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2020.113895_b0235","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","article-title":"Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)","volume":"35","author":"Seckl","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0240","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.ejca.2014.08.005","article-title":"Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study","volume":"50","author":"Kim","year":"2014","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.bcp.2020.113895_b0245","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ctrv.2018.06.010","article-title":"The poor design of clinical trials of statins in oncology may explain their failure \u2013 Lessons for drug repurposing","volume":"69","author":"Abdullah","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2020.113895_b0250","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Freed-Pastor","year":"2012","journal-title":"Cell."},{"key":"10.1016\/j.bcp.2020.113895_b0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41419-019-1322-x","article-title":"Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells","volume":"10","author":"G\u00f6bel","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2020.113895_b0260","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"Deshayes","year":"2005","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2020.113895_b0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0270","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","article-title":"The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis","volume":"151","author":"Ishikane","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113895_b0275","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcp.22209","article-title":"Angiotensin II\/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase\/Akt pathway","volume":"225","author":"Zhao","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2020.113895_b0280","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/pros.22505","article-title":"Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer","volume":"72","author":"Takahashi","year":"2012","journal-title":"Prostate."},{"key":"10.1016\/j.bcp.2020.113895_b0285","article-title":"Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies","author":"Sun","year":"2017","journal-title":"Medicine (Baltimore). 96"},{"key":"10.1016\/j.bcp.2020.113895_b0290","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2","author":"Murphy","year":"2019","journal-title":"Clinical Trial., JAMA Oncol. 5"},{"key":"10.1016\/j.bcp.2020.113895_b0295","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10637-013-9972-5","article-title":"A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2","volume":"31","author":"Nakai","year":"2013","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.bcp.2020.113895_b0300","first-page":"5837","article-title":"Anti-proliferative effect of digoxin on breast cancer cells via inducing apoptosis","volume":"21","author":"Zhao","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2020.113895_b0305","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/mol.104.007302","article-title":"Digitalis-induced signaling by Na+\/K+-ATPase in human breast cancer cells","volume":"67","author":"Kometiani","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113895_b0310","article-title":"Digoxin suppresses tumor malignancy through inhibiting multiple src-related signaling pathways in non-small cell lung cancer","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.bcp.2020.113895_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178611","article-title":"Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies","volume":"12","author":"Osman","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2020.113895_b0320","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neo.2017.01.010","article-title":"Digoxin Plus trametinib therapy achieves disease control in BRAF Wild-type metastatic melanoma patients","volume":"19","author":"Frankel","year":"2017","journal-title":"Neoplasia."},{"key":"10.1016\/j.bcp.2020.113895_b0325","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2020.113895_b0330","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bcp.2020.113895_b0335","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1940-6207.CAPR-16-0241","article-title":"Unlocking Aspirin\u2019s chemopreventive activity: role of irreversibly inhibiting platelet cyclooxygenase-1","volume":"10","author":"Lichtenberger","year":"2017","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.bcp.2020.113895_b0340","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.2147\/CMAR.S175212","article-title":"Advances in antitumor effects of NSAIDs","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bcp.2020.113895_b0345","article-title":"Evaluation of antitumor effects of aspirin and LGK974 drugs on cellular signaling pathways, cell cycle and apoptosis in colorectal cancer cell lines compared to oxaliplatin drug","volume":"fcp.12492","author":"Bagheri","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113895_b0350","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2019.06.048","article-title":"Aspirin targets P4HA2 through inhibiting NF-\u03baB and LMCD1-AS1\/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma","volume":"45","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2020.113895_b0355","first-page":"383","article-title":"A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells","volume":"9","author":"Goel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.113895_b0360","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/bbrc.2001.4637","article-title":"Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells","volume":"282","author":"Jiang","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2020.113895_b0365","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/cancers10080253","article-title":"Antithrombotic agents and cancer","volume":"10","author":"Bruno","year":"2018","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.bcp.2020.113895_b0370","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/09537104.2018.1492105","article-title":"Aspirin, platelet inhibition and cancer prevention","volume":"29","author":"Patrignani","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.bcp.2020.113895_b0375","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"26","author":"Cuzick","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0380","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2337\/dc18-0368","article-title":"JPAD trial investigators, effect of aspirin on cancer chemoprevention in japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial","volume":"41","author":"Okada","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.bcp.2020.113895_b0385","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.3748\/wjg.v22.i13.3679","article-title":"Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?","volume":"22","author":"Burr","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2020.113895_b0390","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/S0140-6736(18)31775-6","article-title":"seAFOod collaborative group, eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 \u00d7 2 factorial trial","volume":"392","author":"Hull","year":"2018","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.bcp.2020.113895_b0395","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cancers11010046","article-title":"Direct oral anticoagulant drugs: on the treatment of cancer-related venous thromboembolism and their potential anti-neoplastic effect","volume":"11","author":"Grandoni","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.bcp.2020.113895_b0400","article-title":"Low molecular weight heparin as A therapeutic tool for cancer; special emphasis on breast cancer","volume":"11","author":"Sumanasekera","year":"2018","journal-title":"Biomed. J. Sci. Tech. Res."},{"key":"10.1016\/j.bcp.2020.113895_b0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(97)89484-3","article-title":"Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis","volume":"100","author":"Siragusa","year":"1996","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0410","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/s-0037-1615937","article-title":"Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread","volume":"82","author":"Hettiarachchi","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2020.113895_b0415","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","article-title":"Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism","volume":"23","author":"Lee","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0420","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2014-03-561761","article-title":"The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?","volume":"124","author":"Barni","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.bcp.2020.113895_b0425","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)","volume":"22","author":"Kakkar","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0430","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","article-title":"The effect of low molecular weight heparin on survival in patients with advanced malignancy","volume":"23","author":"Klerk","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0435","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1756-9966-27-4","article-title":"Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review","volume":"27","author":"Akl","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.113895_b0440","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2013.09.026","article-title":"Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study","volume":"132","author":"Lecumberri","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bcp.2020.113895_b0445","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"Sanford","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2020.113895_b0450","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0455","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0460","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0465","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","author":"Meyer","year":"2018","journal-title":"Eur. Respir. J. 52"},{"key":"10.1016\/j.bcp.2020.113895_b0470","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdr524","article-title":"Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the \u201cSENDO experience\u201d","volume":"23","author":"Mandala","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bcp.2020.113895_b0475","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/TACG.S96233","article-title":"Marfan syndrome: current perspectives","volume":"9","author":"Pepe","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.bcp.2020.113895_b0480","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","article-title":"The effect of beta-blocker therapy on clinical outcome in patients with Marfan\u2019s syndrome: a meta-analysis","volume":"114","author":"Gersony","year":"2007","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113895_b0485","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1111\/j.1651-2227.2011.02293.x","article-title":"The effect of beta-blocker therapy on progressive aortic dilatation in children and adolescents with Marfan\u2019s syndrome: a meta-analysis","volume":"100","author":"Gao","year":"2011","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bcp.2020.113895_b0490","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011103","article-title":"Beta-blockers for preventing aortic dissection in Marfan\u2019s syndrome","author":"Koo","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bcp.2020.113895_b0495","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3349\/ymj.2016.57.1.81","article-title":"The beneficial effect of renin-angiotensin-aldosterone system blockade in marfan syndrome patients after aortic root replacement","volume":"57","author":"Lee","year":"2016","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.bcp.2020.113895_b0500","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113895_b0505","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/CIRCGENETICS.114.000950","article-title":"Beneficial outcome of losartan therapy depends on type of FBN1 mutation in marfan syndrome","volume":"8","author":"Franken","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.bcp.2020.113895_b0510","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12471-016-0905-8","article-title":"The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations","volume":"24","author":"den Hartog","year":"2016","journal-title":"Neth. Heart J."},{"key":"10.1016\/j.bcp.2020.113895_b0515","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","article-title":"Marfan Sartan: a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Milleron","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113895_b0520","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Pediatric Heart Network Investigators, Atenolol versus losartan in children and young adults with Marfan\u2019s syndrome","volume":"371","author":"Lacro","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0525","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijcard.2014.11.082","article-title":"A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes","volume":"179","author":"Sandor","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113895_b0530","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1358863X15569868","article-title":"Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome","volume":"20","author":"Bhatt","year":"2015","journal-title":"Vasc. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0535","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/eurheartj\/ehv575","article-title":"Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial","volume":"37","author":"Forteza","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113895_b0540","article-title":"The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis","author":"Kang","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.bcp.2020.113895_b0545","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jacc.2018.07.052","article-title":"Losartan versus atenolol for prevention of aortic dilation in patients with marfan syndrome","volume":"72","author":"Teixido-Tura","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.113895_b0550","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pedneo.2017.07.005","article-title":"Losartan in combination with propranolol slows the aortic root dilatation in neonatal Marfan syndrome","volume":"59","author":"Liu","year":"2018","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.bcp.2020.113895_b0555","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","article-title":"Chronic migraine treatment trial research group, randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.bcp.2020.113895_b0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"Jackson","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2020.113895_b0565","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1128\/AAC.00192-16","article-title":"Is there potential for repurposing statins as novel antimicrobials?","volume":"60","author":"Hennessy","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2020.113895_b0570","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3952","article-title":"Statins: antimicrobial resistance breakers or makers?","volume":"5","author":"Ko","year":"2017","journal-title":"PeerJ."},{"key":"10.1016\/j.bcp.2020.113895_b0575","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/138920111798281027","article-title":"Simvastatin is protective during Staphylococcus aureus pneumonia","volume":"12","author":"McDowell","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bcp.2020.113895_b0580","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2180-12-73","article-title":"Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia","volume":"12","author":"Boyd","year":"2012","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.bcp.2020.113895_b0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024394","article-title":"Studies on the Antibacterial Effects of Statins - In Vitro and In Vivo","volume":"6","author":"Bergman","year":"2011","journal-title":"PLoS One."},{"key":"10.1016\/j.bcp.2020.113895_b0590","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1592\/phco.29.6.621","article-title":"Reduction in mortality associated with statin therapy in patients with severe sepsis","volume":"29","author":"Dobesh","year":"2009","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.bcp.2020.113895_b0595","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/IDR.S156475","article-title":"Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis","volume":"11","author":"Tariq","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.bcp.2020.113895_b0600","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1186\/cc11895","article-title":"Randomized double-blind placebo-controlled trial of 40 mg\/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)","volume":"16","author":"Patel","year":"2012","journal-title":"Crit. Care."},{"key":"10.1016\/j.bcp.2020.113895_b0605","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.201209-1718OC","article-title":"ANZ-STATInS Investigators\u2013ANZICS Clinical Trials Group, A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis","volume":"187","author":"Kruger","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2020.113895_b0610","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet. Respir. Med."},{"key":"10.1016\/j.bcp.2020.113895_b0615","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chest.2017.05.017","article-title":"A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with pseudomonas aeruginosa","volume":"152","author":"Bedi","year":"2017","journal-title":"Chest."},{"key":"10.1016\/j.bcp.2020.113895_b0620","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jama.2013.280031","article-title":"STATIN-VAP Study Group, Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial","volume":"310","author":"Papazian","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2020.113895_b0625","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2036.2012.05161.x","article-title":"Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate\u2013a placebo-controlled study","volume":"36","author":"Nseir","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113895_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107483","article-title":"Antifungal effects of statins","author":"Tavakkoli","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113895_b0635","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1574-6968.2006.00370.x","article-title":"Growth inhibition of Candida species and Aspergillus fumigatus by statins","volume":"262","author":"Macreadie","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.bcp.2020.113895_b0640","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/4f388450-90fe-4c65-9b9b-71a2b7935ac0","article-title":"Targeting Iron acquisition blocks infection with the Fungal Pathogens Aspergillus fumigatus and Fusarium oxysporum","volume":"9","author":"Leal","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.113895_b0645","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijfoodmicro.2018.11.012","article-title":"Antifungal activity of silver nanoparticles and simvastatin against toxigenic species of Aspergillus","volume":"291","author":"Bocate","year":"2019","journal-title":"Int. J. Food Microbiol."},{"key":"10.1016\/j.bcp.2020.113895_b0650","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/fgbi.1998.1093","article-title":"Lovastatin triggers an apoptosis-like cell death process in the fungusmucor racemosus","volume":"25","author":"Roze","year":"1998","journal-title":"Fungal Genet. Biol."},{"key":"10.1016\/j.bcp.2020.113895_b0655","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s10096-009-0787-4","article-title":"Statins are associated with improved outcomes of bloodstream infection in solid-organ transplant recipients","volume":"28","author":"Hsu","year":"2009","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.bcp.2020.113895_b0660","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2334-10-152","article-title":"Statins in Candidemia: clinical outcomes from a matched cohort study","volume":"10","author":"Forrest","year":"2010","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.bcp.2020.113895_b0665","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4065\/mcp.2010.0447","article-title":"Statin therapy and decreased incidence of positive candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery","volume":"85","author":"Spanakis","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcp.2020.113895_b0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077317","article-title":"Effect of statin use on outcomes of adults with candidemia","author":"Cuervo","year":"2013","journal-title":"PLoS One. 8"},{"key":"10.1016\/j.bcp.2020.113895_b0675","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13693786.2012.692490","article-title":"Candidemia outcomes not improved with statin use","volume":"51","author":"Welch","year":"2013","journal-title":"Med. Mycol."},{"key":"10.1016\/j.bcp.2020.113895_b0680","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1111\/j.1439-0507.2010.01957.x","article-title":"Case-control study of statin prevention of mould infections","volume":"54","author":"Thompson","year":"2011","journal-title":"Mycoses."},{"key":"10.1016\/j.bcp.2020.113895_b0685","first-page":"53","article-title":"Regulation of osteoclast differentiation by statins","volume":"3","author":"Grasser","year":"2003","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bcp.2020.113895_b0690","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1902\/jop.2005.76.2.295","article-title":"Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells","volume":"76","author":"Yazawa","year":"2005","journal-title":"J. Periodontol."},{"key":"10.1016\/j.bcp.2020.113895_b0695","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6831-8-16","article-title":"Statin use is associated with fewer periodontal lesions: a retrospective study","author":"Lindy","year":"2008","journal-title":"BMC Oral Health. 8"},{"key":"10.1016\/j.bcp.2020.113895_b0700","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1902\/jop.2016.160384","article-title":"The effect of locally delivered statins on treating periodontal intrabony defects: a systematic review and meta-analysis","volume":"88","author":"Sinjab","year":"2017","journal-title":"J. Periodontol."},{"key":"10.1016\/j.bcp.2020.113895_b0705","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1902\/jop.2016.150706","article-title":"1.2% rosuvastatin versus 1.2% atorvastatin gel local drug delivery and redelivery in treatment of intrabony defects in chronic periodontitis: a randomized placebo-controlled clinical trial","volume":"87","author":"Pradeep","year":"2016","journal-title":"J. Periodontol."},{"key":"10.1016\/j.bcp.2020.113895_b0710","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1902\/jop.2016.130227","article-title":"Efficacy of subgingivally delivered 1.2% atorvastatin in the treatment of chronic periodontitis in patients with type 2 diabetes mellitus: a randomized controlled clinical trial","volume":"87","author":"Kumari","year":"2016","journal-title":"J. Periodontol."},{"key":"10.1016\/j.bcp.2020.113895_b0715","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s11255-018-1814-0","article-title":"Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials","volume":"50","author":"Ma","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.bcp.2020.113895_b0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/831748","article-title":"Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide","author":"Al-Otaibi","year":"2012","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bcp.2020.113895_b0725","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jphs.2016.03.006","article-title":"Atorvastatin attenuates contrast-induced nephropathy by modulating inflammatory responses through the regulation of JNK\/p38\/Hsp27 expression","volume":"131","author":"He","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2020.113895_b0730","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/0886022X.2017.1361838","article-title":"Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4\/MyD88 signaling pathway","volume":"39","author":"Yue","year":"2017","journal-title":"Ren. Fail."},{"key":"10.1016\/j.bcp.2020.113895_b0735","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3892\/mmr.2017.6251","article-title":"Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro","volume":"15","author":"He","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2020.113895_b0740","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1097\/01.ASN.0000136778.32499.05","article-title":"Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells","volume":"15","author":"Verhulst","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2020.113895_b0745","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40256-016-0164-5","article-title":"Efficacy of short-term statin treatment for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography\/percutaneous coronary intervention: a meta-analysis of 21 randomized controlled trials","volume":"16","author":"Li","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"10.1016\/j.bcp.2020.113895_b0750","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/DDDT.S149106","article-title":"Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2020.113895_b0755","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007384","article-title":"Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: a meta-analysis of 15 randomized controlled trials","volume":"96","author":"Liang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2020.113895_b0760","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/ajkd.2003.50025","article-title":"Predictors of ARF after cardiac surgical procedures","volume":"41","author":"Tuttle","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bcp.2020.113895_b0765","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ejcts\/ezv246","article-title":"Statin initiation and acute kidney injury following elective cardiovascular surgery: a population cohort study in Denmark\u2020","volume":"49","author":"Layton","year":"2016","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.bcp.2020.113895_b0770","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjcard.2012.11.047","article-title":"Effect of statin use on acute kidney injury risk following coronary artery bypass grafting","volume":"111","author":"Layton","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113895_b0775","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1213\/ANE.0b013e3181d8a078","article-title":"Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery","volume":"111","author":"Argalious","year":"2010","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.bcp.2020.113895_b0780","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1053\/j.jvca.2017.04.038","article-title":"Perioperative statins do not prevent acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials","volume":"31","author":"Zhao","year":"2017","journal-title":"J. Cardiothorac. Vasc. Anesth."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:22:40Z","timestamp":1757769760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220301234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":156,"alternative-id":["S0006295220301234"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113895","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113894","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113895"}}